Bionet

Bionet FCF Margin

The Free Cash Flow Margin of Bionet (1784.TWO) as of Nov 2, 2026 is 1.28 %. In the previous year, Free Cash Flow Margin was 5.97 % — a change of -78.54% (lower).

FCF Margin

1.28 %

YoY

-78.54%

Last updated:

Free Cash Flow Margin of Bionet is 2025 1.28 % . Free Cash Flow Margin of Bionet was 2024 5.97 % . It decreases by -78.54% lower compared to the previous year.

The Bionet FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2018
-3.84 TWD
Jan 1, 2019
-1.15 TWD
Jan 1, 2020
4.42 TWD
Jan 1, 2021
-0.30 TWD
Jan 1, 2022
6.30 TWD
Jan 1, 2023
11.25 TWD
Jan 1, 2024
5.97 TWD
Jan 1, 2025
1.28 TWD
The Bionet FCF Margin history
YEARFCF MarginYoY
1.28 %-78.54%
5.97 %-46.89%
11.25 %+78.61%
6.30 %-2,182.20%
-0.30 %-106.85%
4.42 %-483.47%
-1.15 %-70.01%
-3.84 %-23.17%
-5.00 %-3.25%
-5.17 %-151.19%
10.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bionet Stock analysis

What does Bionet do? Bionet Corp. generates revenue through cell therapy, regenerative medicine, and medical big data services. Its main products include umbilical cord blood stem cells, mesenchymal stem cells, and adult peripheral blood stem cells, which are sold to domestic healthcare providers. The company also offers precision medical applications, prenatal testing, and genetic testing services to domestic clients. The firm primarily serves the domestic market within Taipei City, Taipei, focusing on medical and healthcare segments. Bionet Corp. targets healthcare institutions and medical facilities in Taiwan as its primary customers. The company's product portfolio includes stem cell therapies and genetic testing services, which are distributed through its domestic operations. Revenue streams are derived from both the sale of biological products and the provision of specialized medical services within the local market. The business model relies on domestic sales of stem cell-based therapies and genetic testing services. Products such as umbilical cord blood stem cells and mesenchymal stem cells are key revenue drivers, alongside precision medical applications and prenatal testing. All operations are conducted within Taiwan, with no mention of international markets or external partnerships. Bionet is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bionet stock

Free Cash Flow Margin of Bionet is 1.28 % in 2025.

Free Cash Flow Margin of Bionet changed from 5.97 % to 1.28 %, representing a -78.54% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Bionet since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Bionet with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Bionet

All Key Metrics — Bionet